ENB Therapeutics
New York
About ENB Therapeutics
ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Its lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis, and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time-efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market. Its products, as combination therapy with immuno-oncology agents, create a new and superior standard of care that blocks key mechanisms of drug resistance, stimulates the immune system to fight cancer, and prevents cancer from spreading. ENB Therapeutics was founded in 2015 and is headquartered in New York, New York.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $8.2M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2022)
- Website: enbpharma.com
- Phone: (212) 792-2317
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/enb-therapeutics-131933 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.